Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2010 pp 343–365Cite as

Antidiabetika

  • Chapter

  • 685 Accesses

Zusammenfassung

Ziele der Diabetestherapie sind Symptomfreiheit, Verbesserung der Lebensqualität und Vermeidung von Sekundärkomplikationen. Dieses wird nach den Daten mehrerer Studien in erster Linie durch eine möglichst optimale Blutzuckereinstellung erreicht. Für den Typ-1-Diabetes ist die Wirkung der Blutzuckereinstellung durch die DCCT-Studie gesichert (Diabetes Control and Complications Trial Research Group 1993). Eine Nachuntersuchung der Patienten betätigte, dass sogar 17 Jahre nach Beendigung der DCCT-Studie das Risiko für kardiovaskuläre Ereignisse durch die intensivierte Therapie um 42% gesenkt wurde (The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group 2005).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2009): Empfehlungen zur antihy-perglykämischen Therapie des Diabetes mellitus Typ 2. 2. Auflage 2009 Arzneiverordnung in der Praxis, Band 36, Sonderheft 1 (Therapieempfehlungen) März 2009. Internet: www.akdae.de/Arzneimitteltherapie/TE/Archiv/Diabetes.pdf

  • Arzneimittelkommission der deutschen Ärzteschaft (2008): Pankreatitis unter Exenatid. Dtsch Ärztebl 105: A 409

    Google Scholar 

  • Berger M, Köbberling J, Windeler J (1996): Wirksamkeit und Wertigkeit der Acarbose. Dtsch Ärztebl 93: B-443–444.

    Google Scholar 

  • Black C, Donnelly P, McIntyre L, Royle P, Shepherd J, Thomas S (2007): Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004654.

    Google Scholar 

  • Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group (2009): Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39–47.

    Article  PubMed  CAS  Google Scholar 

  • Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW et al. (1994): The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 121: 928–935.

    PubMed  CAS  Google Scholar 

  • Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M for the STOP-NIDDM Trail Research Group (2002): Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072–2077.

    Article  PubMed  CAS  Google Scholar 

  • Damsbo P, Clausen P, Marbury TC, Windfeld K (1999): A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 22: 789–794.

    Article  PubMed  CAS  Google Scholar 

  • Deacon CF (2009): Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 5: 199–211.

    Article  PubMed  CAS  Google Scholar 

  • Diabetes Control and Complications Trial Research Group (1993): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986.

    Article  Google Scholar 

  • Diamant M, Heine RJ (2003): Thiazolidinediones in type 2 diabetes mellitus. Drugs 63: 1373–1405.

    Article  PubMed  CAS  Google Scholar 

  • Dills DG, Schneider J (1996): Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 28: 426–429.

    Article  PubMed  CAS  Google Scholar 

  • Dormandy JA, Charbonnel B, Eckland DA, Erdmann E, Massi-Benedetti M et al. (2005): Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVa-scular Events): a randomised controlled trial. Lancet 366: 1279–1289.

    Article  PubMed  CAS  Google Scholar 

  • Draeger KE, Wernicke-Panten K, Lomp H-J, Schüler E, Roßkamp R (1996): Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibenclamide. Horm Metab Res 28: 419–425.

    Article  PubMed  CAS  Google Scholar 

  • Drucker DJ, Nauck MA (2006): The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696–1705.

    Article  PubMed  CAS  Google Scholar 

  • Freemantle N (2005): How well does the evidence on pioglitazone back up researchers’ claims for a reduction in macrovascular events? BMJ 331: 836–838.

    Article  PubMed  Google Scholar 

  • Gale EAM for the UK Trial Group (2000): A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. Diabetic Med 17: 209–214.

    Article  Google Scholar 

  • Gemeinsamer Bundesausschuss (2006): Medizinische Versorgung von Diabetes-Typ-2-Patienten gesichert. G-BA schützt Solidargemeinschaft vor überteuerten Pharmapreisen. Pressemitteilung vom 18.07.2006. Im Internet: www.g-ba.de/downloads/39-261-313/2006-07-18-AMR-Insulinanaloga_BAnz.pdf

  • Gemeinsamer Bundesausschuss (2008a): Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie in Anlage 4: Therapiehinweis zu Sitagliptin vom 10. April 2008. Dtsch Ärztebl 105: A 1801–A 1804.

    Google Scholar 

  • Gemeinsamer Bundesausschuss (2008b): Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie in Anlage 4: Therapiehinweis zu Exenatide vom 19. Juni 2008/16. Oktober 2008. Dtsch Ärztebl 106: A 727–A 729.

    Google Scholar 

  • Gemeinsamer Bundesausschuss (2009a): Beschluss des Gemeinsamen Bundesausschusses über die Einleitung eines Stellungnahmeverfahrens zur Änderung der Arzneimittel-Richtlinie in Anlage III: Glitazone zur Behandlung des Diabetes mellitus Typ 2 Vom 28. Mai 2009. Internet: www.g-ba.de/downloads/39-261-836/2009-05-28-AMR3_Glitazone.pdf

  • Gemeinsamer Bundesausschuss (2009b): Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III – Übersicht der Verordnungseinschränkungen und -ausschlüsse. Lang wirkende Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2 Vom 18. März 2010. Internet: www.g-ba.de/downloads/39-261-1109/2010-03-18-AMR3_Insulinanaloga_Typ2.pdf

  • Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004): Acarbo-se reduziert das Risiko für einen Myocardinfarkt bei Typ 2 Diabetikern: Metaanalyse von sieben Langzeitstudien. European Heart Journal 25: 10–16.

    Article  PubMed  CAS  Google Scholar 

  • Harris G (2010): Research ties diabetes drug to heart woes. New York Times, February 20, 2010. Internet: www.nytimes.com/2010/02/20/health/policy/20avandia. html?pa

  • Hollander PA, Zheng H, Schwartz SL, Foley JE, Gatlin MR, Dunning BE, Haas SJ (2001): Importance of early insulin secretion. Comparison of nateglinide and gly-buride in previously diet-treated patients with type 2 diabetes. Diabetes Care 24: 983–988.

    Article  PubMed  CAS  Google Scholar 

  • Holman RR, Mayon White V, Orde-Peckar C, Steemson J, Smith B et al. (1983): Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients: a two-year randomised prospective study. Lancet: 204–208.

    Google Scholar 

  • Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008): 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577–1589.

    Article  PubMed  CAS  Google Scholar 

  • Holman RR, Cull CA, Turner RC (1999): A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 22: 960–964.

    Article  PubMed  CAS  Google Scholar 

  • Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ (2007): Rosiglitazone evaluated for cardiovascular outcomes – An interim analysis. N Engl J Med 357: 28–38.

    Article  PubMed  CAS  Google Scholar 

  • Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team (2009): Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373: 2125-2135.

    Article  PubMed  CAS  Google Scholar 

  • Institut für Wirtschaftlichkeit und Qualität im Gesundheitswesen (IQWiG) (2005): Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2. Abschlussbericht. Im Internet: www.iqwig.de/index.140.html

  • Institut für Wirtschaftlichkeit und Qualität im Gesundheitswesen (IQWiG) (2009): Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2. Abschlussbericht. Im Internet: www.iqwig.de/download/A05-03_Abschlussbe-richt_Langwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_2_V1.1.pdf

  • Joffe HV (2009): Endocrinologic and Metabolic Drugs Advisory Committee Meeting Advisory Committee, April 1 and April 2, 2009. Internet: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinologicand-MetabolicDrugsAdvisoryCommittee/UCM151114.pdf

  • Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O‘Neill MC, Zinman B, Viberti G; ADOPT Study Group (2006): Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–1443.

    Article  PubMed  CAS  Google Scholar 

  • Keating GM (2005): Exenatide. Drugs 65: 1681–1692.

    Article  PubMed  CAS  Google Scholar 

  • Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group (2002): Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403.

    Article  PubMed  CAS  Google Scholar 

  • Landgraf R, Bilo HJ, Müller PG (1999): A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 55: 165–171.

    Article  PubMed  CAS  Google Scholar 

  • Laube H (2002): Acarbose. An update of its therapeutic use in diabetes treatment. Clin Drug Invest 22: 141–156.

    Article  CAS  Google Scholar 

  • Marbury T, Huang WC, Strange P, Lebovitz H (1999): Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract. 43: 155–166.

    CAS  Google Scholar 

  • Mathaei S, Bierwirth R, Fritsche A, Gallwitz B, Häring HU, Joost HG, Kellerer M, Kloos C, Kunt T, Nauk M, Schernthaner G, Siegel E, Thienel F (2009) Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. Diabetologie 4: 32–64. Internet: www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Dm_Typ2_Update_2008.pdf

  • Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, Masotti G, Marchionni N, Mannucci E (2006): Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 22 (2006) 477–482.

    Article  PubMed  CAS  Google Scholar 

  • Moses R (2000): A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert Opin Pharmacother 1: 1455–1467.

    Article  PubMed  CAS  Google Scholar 

  • Nathan DM (2006): Thiazolidinediones for initial treatment of type 2 diabetes? N Engl J Med 355: 2477–2480.

    Article  PubMed  CAS  Google Scholar 

  • Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for the Study of Diabetes (2009): Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52: 17–30.

    Article  PubMed  CAS  Google Scholar 

  • Nissen SE (2010): Setting the RECORD straight. JAMA 303: 1194–1195.

    Article  PubMed  CAS  Google Scholar 

  • Nissen SE, Wolski K (2007): Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. Engl J Med 356: 2457–2471.

    Article  CAS  Google Scholar 

  • Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group (2005): The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142: 611–619.

    PubMed  CAS  Google Scholar 

  • Rao AD, Kuhadiya N, Reynolds K, Fonseca VA (2008): Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies. Diabetes Care 31: 1672–1678.

    Article  PubMed  Google Scholar 

  • Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N (2009): Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373: 1765–1772.

    Article  PubMed  CAS  Google Scholar 

  • Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C (2008): Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 4: 753–768.

    PubMed  CAS  Google Scholar 

  • Scheen AJ (2003): Is there a role for alpha-Glucosidase inhibitors in the prevention of type 2 diabetes mellitus?. Drugs 63: 933–951.

    Article  PubMed  CAS  Google Scholar 

  • Scheen AJ, Lethiexhe MR, Lefèbvre PJ (1999): Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of Type 1 diabetic patients on a basal-bolus insulin scheme. Diabetes Metab 25: 157–162.

    PubMed  CAS  Google Scholar 

  • Schernthaner G, Forst T, Gulba D, Haberbosch W, Hanefeld M, Linss G, März W, Mehnert H, Rosak C, Schnell O, Seufert J, Tschöpe D, Erdmann E (2009): Herausforderung Diabetestherapie: Effekte von Glitazonen jenseits der Blutzuckerkontrolle. Dtsch Med Wochenschr 134: 949–954.

    Article  PubMed  CAS  Google Scholar 

  • Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR (2004): Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003287.

    Google Scholar 

  • Smith U, Gale EA (2009): Does diabetes therapy influence the risk of cancer? Diabetologia 52: 1699–1708.

    Article  PubMed  CAS  Google Scholar 

  • Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE et al. (2000): Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 321: 405–412.

    Article  PubMed  CAS  Google Scholar 

  • Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE (1995): Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333: 550–554.

    Article  PubMed  CAS  Google Scholar 

  • Takeda Pharma (2007): Wichtige Sicherheitsinformation zu Frakturen unter Pioglita-zon-Einnahme. Internet: www.akdae.de/20/40/Archiv/2007/54-20070402.pdf

  • The Action to Control Cardiovascular Risk in Diabetes Study Group (2008): Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559 (ACCORD study).

    Article  Google Scholar 

  • The ADVANCE Collaborative Group (2008): Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560–2572 (ADVANCE study).

    Article  Google Scholar 

  • The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005): Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643–2653.

    Article  Google Scholar 

  • Tuomilehto J, Lindstrom J, Eriksson JG, Valle T T, Hamalainen H et al. for the Finnish Diabetes Prevention Study Group (2001): Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350.

    Article  PubMed  CAS  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998a): Intensive glood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853.

    Article  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998b): Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865.

    Article  Google Scholar 

  • United States Senate (2010): Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia. Prepared by the staff of the Committee on Finance, United States Senate, Max Baucus, Chairman, Chuck Grassley, Ranking Member. http://finance.senate. gov/press/Gpress/2010/prg022010a.pdf.

  • Warren E, Weatherley-Jones E, Chilcott J, Beverley C (2004): Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 8: 1–57.

    CAS  Google Scholar 

  • Wilde MI, McTavish D (1997): Insulin Lispro. A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54: 597–614.

    Article  PubMed  CAS  Google Scholar 

  • Wolffenbuttel BHR, Landgraf R on behalf of the Dutch and German Repaglinide Study Group (1999): A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care 22: 463–467.

    Article  PubMed  CAS  Google Scholar 

  • Yki-Jarvinen H (2006): The PROactive study: some answers, many questions. Lancet 366: 1241–1242.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Höferstraße 15, 68199, Mannheim

    Dr. med. Klaus Mengel

Authors
  1. Dr. med. Klaus Mengel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein, Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mengel, K. (2010). Antidiabetika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2010. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13380-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-13380-0_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-13379-4

  • Online ISBN: 978-3-642-13380-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation